- Home
- WINA vs XNCR Comparison
WINA vs XNCR Comparison
Compare WINA & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WINA | XNCR |
|---|---|---|
| Founded | 1988 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2006 | 2013 |
Fundamental Metrics
Financial Performance| Metric | WINA | XNCR |
|---|---|---|
| Price | $383.41 | $14.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 33.2K | ★ 958.3K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | 3.76 | ★ 65.36 |
| EPS | ★ 2.50 | N/A |
| Revenue | $86,055,700.00 | ★ $125,576,000.00 |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $6.03 | $4.80 |
| P/E Ratio | $152.51 | ★ N/A |
| Revenue Growth | 5.86 | ★ 13.65 |
| 52 Week Low | $338.18 | $6.92 |
| 52 Week High | $526.81 | $18.69 |
Technical Indicators
Market Signals| Indicator | WINA | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 55.40 |
| Support Level | $362.23 | $10.94 |
| Resistance Level | $393.93 | $15.59 |
| Average True Range (ATR) | 16.24 | 0.89 |
| MACD | -6.39 | -0.11 |
| Stochastic Oscillator | 3.55 | 18.71 |
Price Performance
Historical ComparisonAbout WINA Winmark Corporation
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment, including Franchising, and one non-reportable segment, Leasing. The franchising segment franchises value-oriented retail stores that buy, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes the middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.